CN101820896A - 用于治疗雷特综合征和突触病症的igf - Google Patents

用于治疗雷特综合征和突触病症的igf Download PDF

Info

Publication number
CN101820896A
CN101820896A CN200880024937A CN200880024937A CN101820896A CN 101820896 A CN101820896 A CN 101820896A CN 200880024937 A CN200880024937 A CN 200880024937A CN 200880024937 A CN200880024937 A CN 200880024937A CN 101820896 A CN101820896 A CN 101820896A
Authority
CN
China
Prior art keywords
igf
igf1
analogs
administered
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880024937A
Other languages
English (en)
Chinese (zh)
Inventor
姆里甘卡·苏尔
达妮埃拉·特罗佩亚
埃马努埃拉·科梅蒂
鲁道夫·耶尼施
纳撒·R·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Original Assignee
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research filed Critical Massachusetts Institute of Technology
Publication of CN101820896A publication Critical patent/CN101820896A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN200880024937A 2007-06-08 2008-06-06 用于治疗雷特综合征和突触病症的igf Pending CN101820896A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93373807P 2007-06-08 2007-06-08
US60/933,738 2007-06-08
PCT/US2008/007107 WO2008153929A1 (en) 2007-06-08 2008-06-06 Igf for the treatment of rett syndrome and synaptic disorders

Publications (1)

Publication Number Publication Date
CN101820896A true CN101820896A (zh) 2010-09-01

Family

ID=39891784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880024937A Pending CN101820896A (zh) 2007-06-08 2008-06-06 用于治疗雷特综合征和突触病症的igf

Country Status (8)

Country Link
US (2) US7994127B2 (enExample)
EP (1) EP2164509A1 (enExample)
JP (1) JP2010529128A (enExample)
CN (1) CN101820896A (enExample)
AU (1) AU2008262387A1 (enExample)
BR (1) BRPI0812768A2 (enExample)
CA (1) CA2689549A1 (enExample)
WO (1) WO2008153929A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108187031A (zh) * 2018-02-11 2018-06-22 中国人民解放军第四军医大学 rhIGF1在制备治疗脆性X综合征药物中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
CN102348798A (zh) 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
EP2571515B1 (en) 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
MX353285B (es) * 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
WO2014085480A1 (en) * 2012-11-28 2014-06-05 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
ES2495266B8 (es) * 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
RU2017110868A (ru) 2014-09-25 2018-10-25 Колд Спринг Харбор Лаборатори Лечение синдрома ретта
JP6866379B2 (ja) 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤
WO2022055045A1 (ko) * 2020-09-08 2022-03-17 주식회사 선마린바이오테크 콜라게나제 저해 활성 펩타이드 유도체 및 이의 용도
US20240148835A1 (en) * 2021-01-28 2024-05-09 University Of Florida Research Foundation, Incorporated Treating disorders associated with dyrk1a dysfunction

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5446024A (en) 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
CA2178711A1 (en) 1993-12-23 1995-06-29 Peter David Gluckman Composition and methods to improve neural outcome
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US7304029B1 (en) 1998-09-03 2007-12-04 Neuren Pharmaceuticals Ltd. Neuroprotective effect of growth hormone
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2002016408A2 (en) 2000-08-24 2002-02-28 Neuronz Ltd. Gpe analogs
WO2002057241A1 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2002056873A2 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7485630B2 (en) 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US20070224165A1 (en) 2003-10-23 2007-09-27 Neuren Pharmaceuticals Limited Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
KR20060040550A (ko) 2004-11-05 2006-05-10 마루이시세이야쿠가부시키가이샤 인슐린유사 성장인자-1 분비촉진제
US8158582B2 (en) 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李美蓉等: "《Rett综合征和DNA甲基化》", 《国际遗传学杂志》 *
韩彩萍等: "《胰岛素样生长因子-1的神经保护作用》", 《国外医学脑血管疾病分册》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108187031A (zh) * 2018-02-11 2018-06-22 中国人民解放军第四军医大学 rhIGF1在制备治疗脆性X综合征药物中的应用

Also Published As

Publication number Publication date
EP2164509A1 (en) 2010-03-24
US7994127B2 (en) 2011-08-09
WO2008153929A1 (en) 2008-12-18
CA2689549A1 (en) 2008-12-18
BRPI0812768A2 (pt) 2014-12-02
JP2010529128A (ja) 2010-08-26
AU2008262387A1 (en) 2008-12-18
US20120177630A1 (en) 2012-07-12
US20090099077A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US7994127B2 (en) Treatment of rett syndrome
US20230381175A1 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
Dong et al. Sitagliptin protects the cognition function of the Alzheimer’s disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings
Abdala et al. Deficiency of GABAergic synaptic inhibition in the Kölliker–Fuse area underlies respiratory dysrhythmia in a mouse model of Rett syndrome
CN105531383B (zh) 神经变性障碍
US20110053859A1 (en) Methods to reduce the effects of sleep deprivation
RS55071B1 (sr) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
Huotarinen et al. Combination of CDNF and deep brain stimulation decreases neurological deficits in late-stage model Parkinson’s disease
US20190076553A1 (en) Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
US20030027755A1 (en) Compositions and methods for the rescue of white matter
US11266715B2 (en) C3A receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders
RU2655811C2 (ru) Терапевтическое средство для бокового амиотрофического склероза
JP6623463B2 (ja) 頭蓋内圧上昇の治療
WO2025179292A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
WO2024256731A2 (en) A cholecystokinin (cck) antagonist for use in the prevention and/or treatment of a vestibular disease or disorder
CN114727981A (zh) 用于挽救视网膜和脉络膜结构和功能的组合物和方法
US10813922B2 (en) Reducing memory loss in mammals suffering from Alzheimer's disease
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
US9586992B2 (en) Amidated dopamine neuron stimulating peptides for CNS dopaminergic upregulation
US20180326014A1 (en) Pharmaceutical formulations for the treatment of diabetes
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
Dhillon On the roles of hypothalamic tanycytes in energy homeostasis
CN118576596A (zh) Lys01或其盐在制备Kir4.1钾离子通道抑制剂中的应用
HK40080560A (en) Compositions and methods for rescuing retinal and choroidal structure and function

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100901

WD01 Invention patent application deemed withdrawn after publication